J.P. Morgan upgrades bluebird bio to 'neutral'

bluebird bio

24/02/2025 11:21

** J.P. Morgan upgrades gene therapy maker bluebird bio
 BLUE.O  to "neutral" from "underweight" rating, citing co's
announcement that it would be taken private
    ** Brokerage expects co's privatization to take place within
1H25
    ** BLUE says it will be taken private by Carlyle  CG.O  and
SK Capital Partners
    ** 1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their
median PT is $10 - LSEG data
    ** As of last close, stock down ~51.1% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)
 ((Prakhar.srivastava2@thomsonreuters.com))